| P/E (FY) | — | Sales (TTM) | €2.6M |
| Earnings (TTM) | -€14.0M | ROE | — |
| Net Margin | −533.37% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | −30.17% |
GenSight Biologics is a clinical-stage biotechnology company developing therapies for neurodegenerative retinal diseases and central nervous system disorders. It builds its candidates on gene therapy and optogenetics platforms, with LUMEVOQ in Phase III trials for leber hereditary optic neuropathy and GS030 in Phase I/II trials for retinitis pigmentosa and dry age-related macular degeneration. The company is headquartered in Paris, France.
| Market Cap | $11.7M | Trading Days | 2520 |
| 52W High | 0.24 |
| 52W Low | 0.08 |
| % Off High | −65.61% |
| YTD | −21.26% | 1Y | −49.69% |
| 3Y | −88.21% | 5Y | −98.97% |
| 10Y | −98.97% | Since incept. (ann.) | −36.74% |
| Ann. Volatility (1Y) | 78.22% | Ann. Volatility (3Y) | 97.87% |
| Sharpe (1Y) | −0.50 | Sharpe (3Y) | −0.32 |
| Max Drawdown (1Y) | −56.01% | Max Drawdown (3Y) | −89.43% |
| Beta (3Y, vs SPY) | 0.62 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| INTS | INTENSITY THERAPEUTICS, INC. | $11.7M | — |
| UEEC | United Health Products, Inc. | $11.7M | — |
| CALC | CalciMedica, Inc. | $11.7M | — |
| PHIO | Phio Pharmaceuticals Corp. | $11.4M | — |
| KPRX | KIORA PHARMACEUTICALS INC | $11.4M | — |
| COCP | Cocrystal Pharma, Inc. | $12.0M | — |
| XCUR | EXICURE, INC. | $11.0M | — |
| BNGO | Bionano Genomics, Inc. | $12.5M | — |
| GTBP | GT Biopharma, Inc. | $10.9M | — |
| INAB | IN8BIO, INC. | $10.5M | — |
| ICU | SeaStar Medical Holding Corp | $13.0M |
| — |
| LGVN | Longeveron Inc. | $10.5M | — |
